Can patents on diagnostic tests survive in the US?

In March 2012 it was controversially held by the US Supreme Court in Mayo Collaborative Services v Prometheus Laboratories Inc. (2012) that a “relationship” between the concentrations of blood metabolites and response to a therapeutic drug, claimed in patents owned by Prometheus Laboratories Inc was not patentable because it represented a “principle of nature”. The Court stated

Push for gene patent ban in Australia resurrected

Seemingly unsatisfied by two recent Senate Inquiry Reports which rejected proposals to legislate against gene patents, the proponents of gene patent reform appear to have resurrected their cause via a new Private Members’ Bill which once again seeks to ban gene patents in Australia. In September 2011, we reported that an attempt to ban gene